At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Sun | Mon | Tue | Wed | Thu | Fri | Sat |
---|---|---|---|---|---|---|
Sun | Mon | Tue | Wed | Thu | Fri | Sat |
---|---|---|---|---|---|---|
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has appointed...
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its drug candidate...
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 2:15 PM EDT in the Intercontinental New York Barclay Hotel in...
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received two...
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 10:25 AM EDT in the Lotte New York Palace Hotel in New...
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has partnered with...
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received an...
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter financial results and provided an overview of recent operational highlights. "During the second quarter, we further strengthened our...
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs for major lung diseases, has announced the appointment of Amit D. Munshi to the Pulmatrix Board of...
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into...